MRTX - FDA clears Mirati's investigational new drug application for its inhibitor MRTX1133

• Mirati Therapeutics ( NASDAQ: MRTX ) on Thursday said the U.S. Food and Drug Administration had cleared its investigational new drug (IND) application for its inhibitor MRTX1133.
• MRTX1133 is an investigational inhibitor that targets a type of mutation in multiple cancer types called KRAS G12D.
• "MRTX1133 has demonstrated favorable properties including a low risk for off-target activity and drug interactions and a predicted human half-life of greater than 50 hours," the company said in a statement .
• The clearance of the IND allows the company to proceed with an early-to-mid stage trial of MRTX1133 which will launch in early 2023.
• Mirati Therapeutics ( MRTX ) stock earlier closed -3.8% at $42.98.

For further details see: